No Carolina / NY / Florida
Ph: 561.316.3330

The University of Edinburgh Acknowledges Pelago Patent and Use of ​CETSA ® Process

Summation

  • “The University of Edinburgh wishes to acknowledge the validity of Pelago's CETSA patent (EP 2 699 910 B1) entitled “Methods For Determining Ligand Binding To A Target Protein Using A Thermal Shift Assay” (the “Patent”) and the use of the Cellular Thermal Shift Assay (CETSA®) process described in the Patent in relation to the following works.
  • I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
  • University of Edinburgh acknowledges Pelago Bioscience's CETSA patent and use thereof in selected works in drug discovery research.

The CETSA

University of Edinburgh acknowledges Pelago Bioscience’s CETSA patent and use thereof in selected works in drug discovery research.

In Connection with the CETSA® Platform, the University of Edinburgh States

“The University of Edinburgh wishes to acknowledge the validity of Pelago’s CETSA patent (EP 2 699 910 B1) entitled “Methods For Determining Ligand Binding To A Target Protein Using A Thermal Shift Assay” (the “Patent”) and the use of the Cellular Thermal Shift Assay (CETSA®) process described in the Patent in relation to the following works: Carolin Temps et al., “A novel mode of inhibiting SRC improves drug efficacy and tolerability”, Cancer Research, 20 August 2021, DOI: 10.1158/0008-5472.CAN-21 0613; Chiara Asselborn, Kevin Myant and Alex von Kriegsheim, “Selective vulnerability of colorectal cancer (CRC) organoids to hypoxia-mimetic drug”, presented at the National Cancer Research Institute Cancer Conference in 2018; and; PhD student research to validate binding between integrin linked kinase and three compounds proposed to bind the protein undertaken in around February 2021”

Michael Dabrowski, CEO of Pelago Bioscience Comments on the Agreement

We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.

For more information about Pelago Bioscience and CETSA technology, please visit: www.pelagobio.com

More News

Ossium Health Launches HOPE Program to Give All Patients Hope for a Cure

Through the HOPE Program, patients across the globe can receive bone marrow from Ossium’s bank free of charge.

Seek Labs Announces Successful Completion of African Swine Fever Virus In Vivo Trial Utilizing CRISPR-based Treatments

The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based systems survived longer than untreated infected pigs. Over half of the CRISPR-treated pigs survived beyond the duration of the trial. Observations and data from both studies reveal compelling outcomes where treatment prolonged lifespans of infected pigs compared to control groups.

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy